Sino Biopharmaceutical Ltd. (SBMFF)
0.8721
0.00 (0.00%)
USD |
OTCM |
Dec 04, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 15.60B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 94.90% |
| Valuation | |
| PE Ratio | 30.49 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.704 |
| Price to Book Value | 4.101 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0064 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.71% |
Profile
| Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong. |
| URL | http://www.sinobiopharm.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 02, 2025 |
Ratings
Profile
| Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong. |
| URL | http://www.sinobiopharm.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 02, 2025 |